key: cord-0735115-6zzufxnx
authors: Zhang, Xuchang; Jiang, Man; Yang, Jianshe
title: Potential value of circulating endothelial cells for the diagnosis and treatment of COVID-19
date: 2021-05-14
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2021.05.001
sha: 0708472a2cdcb548f21adca91260b383dc255c42
doc_id: 735115
cord_uid: 6zzufxnx

The ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has been a formidable global challenge. As yet, there are very few drugs to treat this infection and no vaccine is currently available. We have gradually come to realize that coronavirus disease 2019 (COVID-19) is not a simple disease involving a single organ; rather, many vital organs and systems are affected. The endothelium is also a target of SARS-CoV-2. Damaged endothelial cells, which break away from organs and enter the blood to form circulating endothelial cells, were recently reported as putative biomarkers for COVID-19. Additionally, by modulating the expression level of sphingosine-1 phosphate via sphingosine kinase activation, endothelial cell proliferation and apoptosis can be controlled. Thus, it may be possible to obtain a sensitive and specific diagnosis of COVID-19 severity by assessing the absolute number and the viable/apoptotic ratio of circulating endothelial cells. Furthermore, a focus on the endothelium could help to develop a strategy for COVID-19 treatment from the perspective of endothelium protection and repair.

Keywords: SARS-CoV-2, endothelial cell, diagnosis, treatment Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread throughout the world. To date, more than 33 million people have had a confirmed diagnosis of coronavirus disease 2019 , and over 1 million people have died from it. At the onset of the COVID-19 pandemic, it was considered to be a mono-organ disease involving lesions; however, the pulmonary system, gastrointestinal system, kidney, heart, and liver have now been identified as targets of SARS-CoV-2 infection (Cheung et al., 2020; Puelles et al., 2020) . The endothelium has also been implicated (Varga et al., 2020) .

A recent study (Guervilly et al., 2020) identified a possible correlation between increased levels of circulating endothelial cells (CECs), which are the deciduous endothelial cells from the injured organs or tissues circulating in blood, and the severity of COVID-19.

The levels of CECs in COVID-19 patients who required intensive care unit (ICU) treatment were significantly higher than in those who did not need ICU treatment.

Additionally, the study found a strong relationship between disease severity and the extent of endothelial injury; thus, the CEC level was postulated as a putative biomarker for COVID-19 severity. Another study reported that the viable/apoptotic CEC ratio was significantly different in COVID-19 patients, although the absolute number of CECs was not significantly different from that of healthy controls (Mancuso et al., 2020) .

Furthermore, as a fraction of CECs are associated with the endothelial progenitor cells, which are possible to be infected by SARS-CoV-2. But in that the stem cells do not J o u r n a l P r e -p r o o f express specific receptors or limited areas of the cell membrane are coved with target receptors, these features limit direct contact and crosstalk between the viruses and stem cells (Bagheri et al., 2021) . This contradiction will make us consider the potential infectious mechanism cautiously, especially in the clinical transplant sourcing from the patients with COVID-19.

The endothelium is one of the largest organs; its primary function as a barrier depends on its homeostasis. A recent study demonstrated that COVID-19 patients have a higher risk of severe outcomes when they have hypertension or diabetes comorbidities, which can cause endothelium damage (Levi et al., 2020) . Endothelial cells in children typically have a more complete structure and they function better compared with those in adults;

consequently, the endothelium tissue in children is more resistant to viral attack (Hepponstall et al., 2017) . Adverse effects of COVID-19, such as hypercoagulation and vascular damage, rarely occur in children with the disease (Ludvigsson et al., 2020) . On the contrary, researchers (Rauch et al., 2020) provided the results of a functional assay demonstrating a direct effect of dysregulation of immune response on endothelial damage in COVID-19, declared that the endothelial damage is associated with immunopathology and may occur in parallel with intracellular SARS-CoV-2 infection. This is a direct evidence with diagnostic value of endothelial damage correlated with COVID-19.

The above findings imply that the absolute number of CECs is closely related to the severity of COVID-19, and the viable/apoptotic CEC ratio is significantly different in COVID-19 patients compared with people who do not have COVID-19. To some extent, J o u r n a l P r e -p r o o f we should consider CECs as a potential biomarker for COVID-19 diagnosis, according to their number and classification.

Many registered clinical trials for COVID-19 have been conducted, such as for antiviral and antimalarial treatments (Lythgoe et al., 2020) , but very few have found a reduction in overall mortality or viral load (Cao et al., 2020) . Cystic fibrosis transmembrane conductance regulator (CFTR) was found to maintain the stability of lung endothelium (Tsai et al., 2016) . CFTR dysfunction can increase endothelial cell permeability and might aggravate lung inflammation. Sphingosine-1 phosphate (S1P), a sphingosine derivative, which has five subtypes (S1P1-S1P5) with diverse expression level modulated by sphingosine kinase (SphK, including SphK1 and SphK2), and regulates the various biofunctions mainly including two parts: stimulating cells proliferation by SphK1 and promoting injured ones apoptosis by SphK2 (Tsai et al., 2016) , has been proven to ameliorate this negative effect. By modulating the S1P expression level via the activation of sphingosine kinase, the proliferation (stimulated by SphK1) and apoptosis (promoted by SphK2) of endothelial cells can be controlled (Mohammed et al., 2017) . Endothelium homeostasis is maintained through these two pathways, making it more resistant to viral and bacterial invasion. Hence, physicians should aim to maintain endothelial function and ameliorate endothelial damage in patients to prevent SARS-CoV-2 infection and to reduce the severity of COVID-19, particularly before there is a material breakthrough in SARS-CoV-2 vaccine and drug development.

A focus on the endothelium and endothelial cells provides us with the opportunity to J o u r n a l P r e -p r o o f

Does the global outbreak of COVID-19 or other viral diseases threaten the stem cell reservoir inside the body?

A Trial of Lopinavir-Ritonavir in adults hospitalized with severe Covid-19

Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from a Hong Kong cohort: systematic review and meta-analysis

Circulating endothelial cells as a marker of endothelial injury in severe COVID -19

Anticoagulation therapy in neonates, children and adolescents

Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults

Ongoing clinical trials for the management of the COVID-19 pandemic

Circulating endothelial progenitors are increased in COVID-19 patients and correlate with SARS-CoV-2 RNA in severe cases

Sphingosine 1-Phosphate: A novel target for lung disorders

Multiorgan and renal tropism of SARS-CoV-2

Endotheliopathy is induced by plasma from critically III patients and associated with organ failure in severe COVID-19

Endothelial cell infection and endotheliitis in COVID-19